Category: $185M

  • Athenex to Acquire Kuur Therapeutics for ~$185M

    Shots: Kuur will receive $70M up front primarily in Athenex common stock and is eligible to receive ~$115 M as a milestone at Athenex’s sole discretion in either cash or additional Athenex common stock (or a combination of both) The acquisition will expand Athenex’s cell therapy development capability with Kuur’s off-the-shelf engineered CAR-NKT platform and […]